Erleada (apalutamide) is now available in a 240 mg tablet for the treatment of patients with non-metastatic castration-resistant prostate cancer, as well as for metastatic castration-sensitive prostate cancer.
Previously, Erleada was only supplied as 60 mg tablets. Health care providers now have the option to prescribe Erleada as either four 60 mg tablets taken once daily, or one 240 mg tablet for patients who prefer to take fewer pills.
For individuals who have difficulty swallowing, the 240 mg tablet can be dispersed in non-carbonated water and then administered with orange juice, applesauce, or additional water. The 60 mg tablet is only approved for mixing with applesauce. The 240 mg tablet may also be administered via a feeding tube.
Erleada, an androgen receptor inhibitor, is supplied as 60 mg tablets in 120-count bottles and 240 mg tablets in 30-count bottles. The product is available via prescription through existing specialty pharmacy networks.
Erleada® (apalutamide), first-and-only next-generation androgen receptor inhibitor with once-daily, single-tablet option now available in the US. News release. The Janssen Pharmaceutical Companies of Johnson & Johnson. Accessed April 3, 2023.
Package insert. Janssen Biotech; 2023. Accessed April 3, 2023.
This article originally appeared on MPR